FOXA1 and breast carcinoma: Further studies have demonstrated that this is likely an indirect manifestation of genetic mutations characteristic of breast carcinomas/triple-negative breast cancer, leading to hyperactivation of the FOXA1 and PI3K/AKT/mTOR signaling pathways [8,9].